Reuters: Regulatory News: UK cost agency backs Medivation, Astellas prostate cancer pill

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Free Bestselling eBooks Free national bestsellers for your eReader - Fiction, Nonfiction & more! Join 1.5 million book lovers now. Sign-up in under 10 seconds to get the free daily email. From our sponsors

UK cost agency backs Medivation, Astellas prostate cancer pill Oct 17th 2013, 23:01 Share this Email Print Reprints LONDON | Thu Oct 17, 2013 7:01pm EDT LONDON Oct 18 (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service. The draft guidance is conditional on Xtandi being provided at an undisclosed discount to the list price of 2,734.67 pounds ($4,400) for 28 days supply, the National Institute for Health and Clinical Excellence (NICE) said on Friday. Xtandi, known chemically as enzalutamide, is designed to treat advanced prostate cancer in patients who have previously received chemotherapy. It is one of four new life-extending prostate cancer drugs that researchers from Britain's Institute of Cancer Research (ICR) have helped to develop in recent years. The others are Johnson & Johnson's Zytiga, Sanofi's Jevtana, and Xofigo from Algeta and Bayer. Alan Ashworth, chief executive of the ICR, said these drugs offered hope for men after decades in which there had been no options once old-style hormone treatment stopped working. "What we're seeing now is an unprecedented period of success for prostate cancer research," he said. "It truly is a golden age for prostate cancer drug discovery and development." Zytiga is already recommended by NICE but Jevtana was rejected as not being cost-effective. The agency has yet to give its verdict on Xofigo, which is on sale in the United States but not yet launched in Europe. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions